HSPB6

Across TCGA pan-cancer cohorts, HSPB6 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HSPB6 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher HSPB6 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated HSPB6 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, GBM, and LSCC are the cancer types where HSPB6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.686	0.347	<.001	86	view →
GBM	OS	Median	All	0.271	0.475	.006	14	view →
LSCC	OS	Median	All	0.936	1.000	.010	11	view →
CCRCC	DFS	Quartile	III,IV	0.140	0.830	.038	10	view →
LUAD	DFS	Median	All	0.886	0.478	.006	4	view →
HNSC	DFS	Median	III,IV	1.000	0.939	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

HSPB6–PDAC (OS)

Open the PDAC breakdown →